CLLS · Cellectis S.A. · Metrics
Market Cap
$98.72M
Shares
100.73M
Volume · Oct 23
13.63K
Avg daily vol (3M)
99.23K
CLLS metrics
66 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.98
Market cap
$98.72M
Price action
20 metricsPrice change (1W)
-5.8%
Price change (30D)
-33.3%
Price change (3M)
-65.5%
Price change (6M)
-74.8%
Price change (YTD)
-79.8%
Price change (1Y)
-71.8%
Trailing year
Price change (5Y)
-90.9%
52-week high
$5.35
52-week low
$0.93
Change from 52-week high
-81.7%
Change from 52-week low
+5.9%
Annualized volatility
82.7%
Annualized volatility (3M)
107.9%
Beta
1.9
RSI (14D)
23.5
Price vs SMA 50
-53.2%
Price vs SMA 200
-68.9%
Avg volume (3M)
99,229
Relative volume
0.1
Average dollar volume
$159,292
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
100.73M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.6×
reciprocal yield 60.8%
P / book
2.4
reciprocal yield 41.6%
FCF yield
-44.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-79.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
100.0%
Operating margin
-96.6%
Trailing 12 months
Net margin
-92.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$58.00M
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-73.0%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-68.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$60.02M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+57.1%
Year over year · more shares
Revenue CAGR (3Y)
+56.1%
Revenue CAGR (5Y)
+7.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-89.1%
Return on assets
-20.8%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
−$91.48M
Free cash flow (TTM)
−$43.80M
Quick ratio
2.5
Interest coverage
-2.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$61.53M
Total assets
$267.37M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$41.62M
Capital expenditures (TTM)
$2.18M
R&D (TTM)
$100.67M
SG&A (TTM)
—
Stock compensation (TTM)
$7.80M
R&D / revenue
167.7%
Stock compensation / revenue
13.0%
Ownership (13F)
9 metrics13F filers
27
13F filer change QoQ
-5
Institutional ownership
9.4%
Conviction holders (share of 13F filers)
3.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-1.7%
Holder tenure
9.4
Price vs estimated holder cost
-25.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.2%
Short interest
3 metricsShort interest
0.3%
Latest settlement · 2.3 days to cover
Days to cover
2.3d
Short-squeeze score
32 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—